• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RCUS

    Arcus Biosciences Inc.

    Subscribe to $RCUS
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

    IPO Year: 2018

    Exchange: NYSE

    Website: arcusbio.com

    Peers

    $CRVS
    $ITOS
    $CANF

    Recent Analyst Ratings for Arcus Biosciences Inc.

    DatePrice TargetRatingAnalyst
    2/26/2025$18.00 → $24.00Neutral → Buy
    H.C. Wainwright
    10/21/2024$20.00Neutral
    H.C. Wainwright
    10/8/2024$29.00Overweight
    Wells Fargo
    11/18/2022$33.00Neutral
    BofA Securities
    10/11/2022$40.00Overweight
    Morgan Stanley
    11/19/2021$42.00 → $53.00Buy
    Citigroup
    11/19/2021$48.00 → $60.00Overweight
    Barclays
    11/18/2021$68.00 → $100.00Outperform
    SVB Leerink
    11/9/2021$45.00 → $48.00Overweight
    Barclays
    10/15/2021$57.00Buy
    BTIG Research
    See more ratings

    Arcus Biosciences Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/27/25 7:06:05 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/27/25 7:05:56 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gilead Sciences, Inc. bought $14,999,996 worth of shares (1,363,636 units at $11.00), increasing direct ownership by 5% to 31,424,760 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/20/25 7:42:29 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gilead Sciences, Inc. bought $319,999,995 worth of shares (15,238,095 units at $21.00), increasing direct ownership by 103% to 30,061,124 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      1/31/24 5:00:35 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcus Biosciences Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of the Company's Board of Directors granted Dr. Markus an option to purchase 305,328 shares of the Company's common stock at an exercise price per share of $12.45, which was the closing price on February 10, 2025, and restricted stock units to acquire a total of 75,193 shares of the Company's common stock. In addition to the awards to Dr. Markus, the Co

      2/11/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

      Dr. Markus will oversee Arcus's clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies   Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus's responsibilities will include oversight of Arcus's clinical development

      1/21/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo

      8/24/22 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer

      Dr. Nuyten will oversee Arcus's clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a and PD-1 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Dimitry S.A. Nuyten, M.D., Ph.D has been appointed chief medical officer (CMO) effective August 1, 2022. In his role as CMO, Dr. Nuyten will oversee Arcus's clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the a

      8/8/22 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Announces New Employment Inducement Grants

      HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 31,600 shares of the Company’s common stock at an exercise price per share of $30.83, which was the closing price on January 8, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08. About Arcu

      1/12/21 4:10:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Appoints Biotech Industry Veteran, Andrew Perlman, M.D., Ph.D. and Gilead’s SVP of Research Biology, Michael Quigley, Ph.D. to Its Board of Directors

      HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman, M.D., Ph.D. and Michael Quigley, Ph.D. have joined the Company’s Board of Directors. Dr. Perlman will also serve as a member of Arcus’s Nominating and Corporate Governance Committee. Drs. Perlman and Quigley both have outstanding track records of success working in innovative and intensely competitive drug discovery and development organizations, including in the fields of oncology and immuno-oncology. “As we head into a pivotal year for Arcus that will include multiple randomize

      1/6/21 4:10:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcus Biosciences Inc. Financials

    Live finance-specific insights

    See more
    • Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

      Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Additional data from the ARC-20 cohorts evaluating casdatifan monotherapy in patients who had progressed on both an anti-PD-1 and a tyrosine kinase inhibitor (TKI) therapy are expected in the fall Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced patients with ccRCC is expected in the second quarter of 2025 Arcus is well positioned

      5/6/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

      New data from the Phase 1/1b ARC-20 cohort evaluating HIF-2a inhibitor casdatifan in combination with cabozantinib in clear cell renal cell carcinoma (ccRCC) will be presented in an oral session by Dr. Toni Choueiri, Dana-Farber Cancer Institute The ASCO presentation will include a more mature data cut than that described in the abstract and will include safety and initial efficacy data for the 100mg casdatifan once-daily (QD) plus 60mg cabozantinib QD cohort Arcus will host a conference call to discuss the ARC-20 data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing diff

      4/23/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

      Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Tuesday, May 6th, 2025 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2025. Investors interested in listening to the conference call may do so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 762544. Participants may also register for the call online using the following link: https://events.q4inc.com/attendee

      4/22/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

      A 9.7-month median progression-free survival (mPFS) was reached for the 50mg twice-daily (BID) casdatifan monotherapy cohort of the Phase 1/1b ARC-20 study; mPFS was not yet reached for other cohorts Across all three monotherapy cohorts presented, casdatifan demonstrated improvements in the rate of primary progression, overall response rate (ORR) and progression-free survival (PFS) relative to published data from studies with HIF-2a inhibitors to date Arcus will host a conference call to discuss these data at 5:00 AM PT / 8:00 AM ET on Tuesday, February 18, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiate

      2/15/25 3:45:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

      New data from ARC-20, a Phase 1/1b study of the HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented in a rapid oral session by Dr. Toni Choueiri, Dana-Farber Cancer Institute The presentation will include initial data from the 100mg once-daily (QD) tablet cohort and updated data for the 50mg twice-daily (BID) and 50mg QD cohorts Arcus will host a conference call to discuss the ARC-20 data at 5:00 AM PT / 8:00 AM ET on Tuesday, February 18, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announc

      2/10/25 5:00:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

      Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising objective response rate (34% with 2 responses pending confirmation, 25% confirmed) for the 100mg daily (50mg twice-daily) cohort of heavily pretreated patients with clear-cell renal cell carcinoma (ccRCC) support a potential best-in-class profile Arcus announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan in combination with volrustomig, an investigational PD-1/CTLA-4 bispecific antibody, in patients with immuno-oncology (IO)-naive ccRCC Data from the randomized ARC-

      11/6/24 4:22:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

      Domvanalimab plus zimberelimab was associated with greater progression-free survival, overall survival, and objective response rate compared with those of zimberelimab or chemotherapy A 36% reduction in risk of death (HR=0.64) was observed for domvanalimab plus zimberelimab compared to zimberelimab alone; zimberelimab reached a median overall survival of two years while the median overall survival for domvanalimab plus zimberelimab was not reached Treatment-related adverse events leading to treatment discontinuation were low (10.5%) for the combination of domvanalimab and zimberelimab relative to chemotherapy (23.5%) Arcus will discuss these results on its earnings call at 2:00 PM

      11/5/24 9:00:00 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

      Objective response rate of 34% (2 responses pending confirmation) and 25% (confirmed) in the 100mg daily dose expansion cohort (n=32) of ARC-20, a Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma (ccRCC) Low rate of primary progression (19%) and high rate of disease control (81%) was observed in the 100mg expansion cohort with many of those patients still on treatment Arcus will host a conference call to discuss these results, including results from the 50mg expansion cohort, at 5:00 AM PT / 8:00 AM ET today Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combinati

      10/24/24 7:30:00 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

      Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended September 30th, 2024. Investors interested in listening to the conference call may do so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 940081. Participants may also register for the call online using the following link: https://www.netroadshow.com/

      10/22/24 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

      Data from the 100mg expansion cohort of ARC-20, a Phase 1/1b study of casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented in an oral plenary session by Dr. Toni Choueiri, Dana-Farber Cancer Institute. Two posters will be presented on the preclinical evaluation and human pharmacokinetics/ pharmacodynamics of casdatifan, respectively, and a third poster will be presented on AB801, Arcus's AXL inhibitor. Arcus will also host a conference call to discuss the ARC-20 results at 5:00 AM PT / 8:00 AM ET on Thursday, October 24, 2024. Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules an

      10/9/24 8:00:00 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcus Biosciences Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/27/25 7:06:05 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/27/25 7:05:56 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gilead Sciences, Inc. bought $14,999,996 worth of shares (1,363,636 units at $11.00), increasing direct ownership by 5% to 31,424,760 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/20/25 7:42:29 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Markus Richard was granted 75,193 shares (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/11/25 9:10:58 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Markus Richard claimed no ownership of stock in the company (SEC Form 3)

      3 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/11/25 9:10:46 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Berger Dietmar claimed no ownership of stock in the company (SEC Form 3)

      3 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      2/10/25 5:15:20 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Tang Carolyn C. was granted 37,000 shares, increasing direct ownership by 37% to 137,623 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      1/27/25 4:31:03 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Rosen Terry J was granted 165,000 shares, increasing direct ownership by 7% to 2,534,360 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      1/27/25 4:30:52 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ribas Antoni

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      1/27/25 4:30:42 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Jarrett Jennifer was granted 50,000 shares, increasing direct ownership by 31% to 213,369 units (SEC Form 4)

      4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

      1/27/25 4:30:32 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcus Biosciences Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

      SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      12/17/24 9:52:58 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

      SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      11/12/24 9:50:12 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcus Biosciences Inc.

      SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      10/17/24 11:31:06 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcus Biosciences Inc. (Amendment)

      SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      2/13/24 4:58:53 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Arcus Biosciences Inc.

      SC 13G - Arcus Biosciences, Inc. (0001724521) (Subject)

      2/9/24 8:35:54 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Arcus Biosciences Inc. (Amendment)

      SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      1/31/24 4:58:44 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Arcus Biosciences Inc.

      SC 13G - Arcus Biosciences, Inc. (0001724521) (Subject)

      1/24/24 7:33:04 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcus Biosciences Inc. (Amendment)

      SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      1/23/24 11:52:27 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Arcus Biosciences Inc. (Amendment)

      SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      7/6/23 9:38:24 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arcus Biosciences Inc. (Amendment)

      SC 13G/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      2/14/23 4:06:45 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcus Biosciences Inc. SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Arcus Biosciences Inc.

      SCHEDULE 13G - Arcus Biosciences, Inc. (0001724521) (Subject)

      5/13/25 5:57:37 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Arcus Biosciences Inc.

      10-Q - Arcus Biosciences, Inc. (0001724521) (Filer)

      5/6/25 4:12:08 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Arcus Biosciences, Inc. (0001724521) (Filer)

      5/6/25 4:09:59 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Arcus Biosciences Inc.

      DEFA14A - Arcus Biosciences, Inc. (0001724521) (Filer)

      4/22/25 4:11:06 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Arcus Biosciences Inc.

      DEF 14A - Arcus Biosciences, Inc. (0001724521) (Filer)

      4/22/25 4:09:20 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Arcus Biosciences Inc.

      SCHEDULE 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      3/5/25 5:00:40 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Arcus Biosciences Inc.

      S-8 - Arcus Biosciences, Inc. (0001724521) (Filer)

      2/25/25 4:18:27 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Arcus Biosciences Inc.

      10-K - Arcus Biosciences, Inc. (0001724521) (Filer)

      2/25/25 4:09:12 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Arcus Biosciences, Inc. (0001724521) (Filer)

      2/25/25 4:07:38 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Arcus Biosciences Inc.

      SCHEDULE 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

      2/20/25 7:43:01 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcus Biosciences Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 21,250 shares of the Company's common stock at an exercise price per share of $8.53, which was the closing price on May 8, 2025, and restricted stock units to acquire a total of 10,650 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2

      5/9/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

      Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Additional data from the ARC-20 cohorts evaluating casdatifan monotherapy in patients who had progressed on both an anti-PD-1 and a tyrosine kinase inhibitor (TKI) therapy are expected in the fall Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan plus cabozantinib versus cabozantinib in IO-experienced patients with ccRCC is expected in the second quarter of 2025 Arcus is well positioned

      5/6/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 39,750 shares of the Company's common stock at an exercise price per share of $8.11, which was the closing price on April 23, 2025 and restricted stock units to acquire a total of 19,950 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2

      4/24/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

      New data from the Phase 1/1b ARC-20 cohort evaluating HIF-2a inhibitor casdatifan in combination with cabozantinib in clear cell renal cell carcinoma (ccRCC) will be presented in an oral session by Dr. Toni Choueiri, Dana-Farber Cancer Institute The ASCO presentation will include a more mature data cut than that described in the abstract and will include safety and initial efficacy data for the 100mg casdatifan once-daily (QD) plus 60mg cabozantinib QD cohort Arcus will host a conference call to discuss the ARC-20 data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing diff

      4/23/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

      Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Tuesday, May 6th, 2025 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended March 31st, 2025. Investors interested in listening to the conference call may do so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 762544. Participants may also register for the call online using the following link: https://events.q4inc.com/attendee

      4/22/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 16,960 shares of the Company's common stock at an exercise price per share of $7.04, which was the closing price on April 8, 2025, and restricted stock units to acquire a total of 8,530 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 20

      4/9/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted twelve new employees options to purchase a total of 42,920 shares of the Company's common stock at an exercise price per share of $9.12, which was the closing price on March 24, 2025, and restricted stock units to acquire a total of 21,650 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in Janua

      3/25/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences to Participate in Two Upcoming Investor Conferences

      Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Healthcare Conference 2025 Date: Wednesday, March 12th, 2025 Location: Miami Beach, FL Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Barclays 27th Annual Global Healthcare Conference Date: Thursday, March 13th, 2025 Location: Miami Beach, FL Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Live webcasts of the fireside chats and panel will be available by visiting the

      2/26/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

      New data from the Phase 1/1b ARC-20 study showed that casdatifan improved upon the rate of primary progression, overall response rate (ORR) and progression-free survival (PFS) relative to published data from studies with HIF-2a inhibitors to date Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan in combination with cabozantinib versus cabozantinib in immuno-oncology (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) is expected in the first half of 2025; initial data from the cohort of ARC-20 evaluating casdatifan plus cabozantinib are expected to be presented in mid-2025 Arcus completed a $150 million financing and continues to be well positioned

      2/25/25 4:05:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 5,550 shares of the Company's common stock at an exercise price per share of $11.07, which was the closing price on February 21, 2025, and restricted stock units to acquire a total of 2,800 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January

      2/24/25 4:35:00 PM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Arcus Biosciences Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Arcus Biosciences upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Arcus Biosciences from Neutral to Buy and set a new price target of $24.00 from $18.00 previously

      2/26/25 7:16:55 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Arcus Biosciences with a new price target

      H.C. Wainwright initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $20.00

      10/21/24 7:58:13 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Arcus Biosciences with a new price target

      Wells Fargo initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $29.00

      10/8/24 7:34:04 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Arcus Biosciences with a new price target

      BofA Securities initiated coverage of Arcus Biosciences with a rating of Neutral and set a new price target of $33.00

      11/18/22 7:57:17 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Arcus Biosciences with a new price target

      Morgan Stanley initiated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $40.00

      10/11/22 7:50:24 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup reiterated coverage on Arcus Biosciences with a new price target

      Citigroup reiterated coverage of Arcus Biosciences with a rating of Buy and set a new price target of $53.00 from $42.00 previously

      11/19/21 9:16:13 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barclays reiterated coverage on Arcus Biosciences with a new price target

      Barclays reiterated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $60.00 from $48.00 previously

      11/19/21 7:43:41 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Arcus Biosciences with a new price target

      SVB Leerink reiterated coverage of Arcus Biosciences with a rating of Outperform and set a new price target of $100.00 from $68.00 previously

      11/18/21 7:54:26 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barclays reiterated coverage on Arcus Biosciences with a new price target

      Barclays reiterated coverage of Arcus Biosciences with a rating of Overweight and set a new price target of $48.00 from $45.00 previously

      11/9/21 7:27:28 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research resumed coverage on Arcus Biosciences with a new price target

      BTIG Research resumed coverage of Arcus Biosciences with a rating of Buy and set a new price target of $57.00

      10/15/21 7:47:13 AM ET
      $RCUS
      Biotechnology: Pharmaceutical Preparations
      Health Care